Danpet AB
Records under this name other than the patents Danpet AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,687,523 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,407,970 | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Term ended Term ended Oct 8, 2024 · From the USPTO record | Term ended | Term ended Oct 8, 2024 | From the USPTO record |
| US 8,158,619 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use Lapsed on the fee record Ended Apr 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2024 | From the USPTO record |
| US 7,220,741 | 1,4-diazabicycloalkane derivatives, their preparation and use Term ended Term ended Sep 29, 2023 · From the USPTO record | Term ended | Term ended Sep 29, 2023 | From the USPTO record |
| US 8,946,412 | Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators Lapsed on the fee record Ended Feb 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 3, 2023 | From the USPTO record |
| US 8,372,832 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use Lapsed on the fee record Ended Feb 12, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2021 | From the USPTO record |
| US 8,986,654 | Labelled and un-labelled methyl-pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use Lapsed on the fee record Ended Mar 24, 2019 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2019 | From the USPTO record |
| US 7,704,991 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Lapsed on the fee record Ended Apr 27, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 27, 2018 | From the USPTO record |
| US 7,687,517 | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Lapsed on the fee record Ended Mar 30, 2018 · From the USPTO record | Lapsed on the fee record | Ended Mar 30, 2018 | From the USPTO record |
| US 6,897,219 | Heteroaryl Diazacycloalkanes, Their Preparation and Use; Lapsed on the fee record Ended May 24, 2017 · Medium confidence | Lapsed on the fee record | Ended May 24, 2017 | Medium confidence |